EMERALD-3: STRIDE Plus Lenvatinib and TACE Extends PFS, Not Yet OS
Analysis Oncology Pharmacy Hypothesis-generating Grade: Moderate
Aug 24, 2026 · Published in: The Lancet. Oncology
Also in Gastroenterology / Hepatology
Combination therapy advances progression-free survival in liver cancer.
Adding Camrelizumab to TACE Plus Donafenib in PVTT-Positive HCC
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Low
Zhang Q, Qing H, Lei Z, et al.
Aug 20, 2026 · Published in: Frontiers in Immunology
Transarterial chemoembolization with donafenib and camrelizumab may extend survival in challenging liver cancer cases.
TDM Not Yet Justified for Non-Anti-TNF IBD Therapies
Analysis Pharmacokinetics / TDM Confirmatory Grade: Low
Chater F, Butler TD, Limdi JK
Aug 19, 2026 · Published in: Frontiers in Gastroenterology (Lausanne, Switzerland)
Also in Gastroenterology / Hepatology
Could TDM unlock better outcomes for advanced IBD therapies?
Naltrexone Safely Triples Abstinence in Compensated Alcohol-Associated Cirrhosis
★ Editor's Pick Analysis Gastroenterology / Hepatology Practice-changing Grade: Moderate
Alla M, Varshney M, Bhardwaj A, et al.
Aug 19, 2026 · Published in: Liver International : Official Journal of the International Association for the Study of the Liver
Also in Behavioral Health / Addiction Medicine
Naltrexone triples abstinence rates in alcohol-associated cirrhosis.
SGLT2 Inhibitors Show No Significant Serious UTI Excess
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Matteucci A, Di Fusco SA, Bonanni M, et al.
Aug 7, 2026 · Published in: Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences
Also in Gastroenterology / Hepatology
SGLT2 inhibitors show no significant rise in UTI risk.
Tegoprazan Matches PPIs for Erosive Esophagitis Healing and Tolerability
Analysis Gastroenterology / Hepatology Confirmatory Grade: Moderate
Diab Y, Maalouf C, Al Hakim AJ, et al.
Jul 29, 2026 · Published in: JGH Open : an Open Access Journal of Gastroenterology and Hepatology
Tegoprazan matches PPIs in treating erosive esophagitis effectively.
Rifaximin Improves Quality of Life in Hepatic Encephalopathy Across Domains
Analysis Gastroenterology / Hepatology Confirmatory Grade: Low
Sacco R, Corti A, Giacomelli L, et al.
Jul 28, 2026 · Published in: Journal of Clinical Medicine
Rifaximin may enhance quality of life for cirrhosis patients with hepatic encephalopathy.
Octreotide for Pediatric Variceal Bleeding: Very Low Certainty Evidence
Analysis Pediatric Pharmacy Inconclusive Grade: Very Low
Kozak A, Nolder G, Ranucci G, et al.
Jul 28, 2026 · Published in: Pharmaceuticals (Basel, Switzerland)
Also in Gastroenterology / Hepatology
Octreotide shows potential in managing pediatric GI bleeding from portal hypertension.
Semaglutide 2.4 mg Dominates Resmetirom in MASH Cost-Effectiveness Model
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Low
McGovern AJ, Cinfio F, Luo R
Jul 26, 2026 · Published in: PharmacoEconomics
Semaglutide 2.4 mg offers cost-effective treatment for MASH.
Terlipressin Linked to Lower In-Hospital Mortality in HRS-AKI
★ Editor's Pick Analysis Nephrology / Renal Pharmacy Hypothesis-generating Grade: Very Low
Johnson HN, Juang PA
Jul 25, 2026 · Published in: The Annals of Pharmacotherapy
Also in Gastroenterology / Hepatology
Terlipressin shows promise in lowering HRS-AKI mortality compared to standard treatments.
Prior Decompensation Flags High Mortality Risk After Variceal Bleeding
Analysis Gastroenterology / Hepatology Confirmatory Grade: Moderate
Turco L, La Mura V, Olivas P, et al.
Jul 22, 2026 · Published in: Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
Prior liver decompensation doubles mortality risk after variceal bleeding.
Rifaximin in Pediatric Hepatic Encephalopathy: First Trial, Ammonia Miss
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Low
Okajima H, Tagawa M, Fujisawa M, et al.
Jul 22, 2026 · Published in: Hepatology Communications
Rifaximin shows promise in pediatric hepatic encephalopathy treatment.
Ustekinumab Salvages Pediatric IBD After Anti-TNF Failure
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Low
Heng Z, Zhan L, Zhang Y, et al.
Jul 20, 2026 · Published in: BMC Gastroenterology
Also in Pediatrics
Could ustekinumab be the answer for pediatric IBD post-anti-TNF failure?
Statins Added to Beta-Blockers Cut Mortality in Compensated Cirrhosis
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Low
Wu Q, Yang Y, Wu Q, et al.
Jul 19, 2026 · Published in: Annals of Hepatology
Also in Clinical Practice
Statins may lower mortality in cirrhosis with portal hypertension.
Fibrosis-Directed MASH Therapeutics Enter the Approved-Drug Era
Analysis Gastroenterology / Hepatology Confirmatory Grade: Low
Li F, Li H, Juramt D, et al.
Jul 2, 2026 · Published in: BMJ Open Gastroenterology
MASLD leads global liver disease, now with targeted therapies emerging.